The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.
/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Regeneron Pharmaceuticals has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.
/Incyte%20Corp_%20phone%20and%20logo-by%20T_Schneider%20via%20Shutterstock.jpg)
Incyte has delivered better returns than the broader market over the past year, and analysts view the stock’s outlook with measured optimism.
/Bio-Techne%20Corp%20site%20magnified%20-by%20Pavel%20Kapysh%20via%20Shutterstock.jpg)
Despite underperforming the broader market and biotechnology industry over the past year, analysts remain strongly bullish on Bio-Techne’s longer-term prospects.
Hunting for upside potential typically reserved for the private equity world? Look no further.
As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter.
Regeneron’s stock has fallen behind the broader market over the past year, but analysts see potential for growth, tempered with caution.
/Incyte%20Corp_%20office%20sign-by%20Bo%20Shen%20via%20iStock.jpg)
Incyte has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.
/Bio-Techne%20Corp%20logo%20and%20data-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Bio-Techne has considerably underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.
/Moderna%20Inc%20meds-by%20Ascannio%20via%20Shutterstock.jpg)
Moderna has significantly underperformed other biotechnology stocks over the past year, and analysts remain cautious on the stock’s prospects.